Pharma Stocks To Watch This Week

  • GSK, NVS,AZN,BIIB,ABBV, ACT,TEVA,RCPT,SYN

This week’s highlights include two major medical conferences, the ERS International Congress 2014 and MSBoston2014. Many large names in the pharmaceutical and biotech sector, such as GlaxoSmithKline plc (ADR) (GSK), Biogen Idec Inc (BIIB), and Abbvie Inc. (ABBV) will present on the experimental drugs in their pipelines and their current development.

ERS International Congress 2014

The ERS Congress is an annual respiratory conference organized by the European Respiratory Society. The conference is being held in Munich and began on September 6. It will last through Tuesday, September 10.

Novartis AG (ADR) (NVS) has already presented in the conference, taking GSK head-on with positive Phase III results for its Ultibro Breezhaler. LANTERN study showed that Ultibro is superior to the respiratory market leader, GSK’s Seretide Bronchodilator, for the treatment of chronic obstructive pulmonary diseases (COPD). Novartis will also present Phase II data today for QGE031, also called Ligelizumab, a drug used to inhibit allergen-induced early asthmatic response.

GSK will fight to maintain its leadership position, presenting Phase III trial results today for its new drug, Mepolizumab, which belongs to a new class of interleukin-5 antibodies. The drug has shown to reduce asthma exacerbations and enhance lung function. This new data will put GSK in line with AstraZeneca plc (ADR) (AZN) and Teva Pharmaceuticals Industries Ltd (ADR) (TEVA), who will also be presenting on similar antibody drugs.

Teva, which already presented yesterday, will again appear on September 10 for its own asthma antibody, Reslizumab. The data presented yesterday shows improved lung function. However, detailed reports will be presented on Friday. Sales for the drug are estimated to be $430 million in 2018, according to Bloomberg intelligence.

AstraZeneca will also present phase II results for Benralizumab, its own interleukin-5 antibody for the treatment of COPD. However, unlike GSK and Teva, the trial data, which was released today before markets opened, has yielded mixed results. The primary endpoint of the trials was not met. AstraZeneca’s stock closed down 1.18% today, on the news.

Good news might come from phase I data for PT010, a therapeutic agent designed for the treatment of COPD, which will also be presented today. The drug was originally developed by Pearl Therapeutics, which was acquired by AstraZeneca last year.

MSBoston2014

The MSBoston is an annual multiple sclerosis (MS) conference held by Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), in collaboration with European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The conference is scheduled to be held on September 10-13 in Boston, Massachusetts. MS is an autoimmune disease estimated to affect 2.3 million individuals worldwide.


The major presentation will include phase III trial data for Biogen and Abbvie’s MS drug, Daclizumab. Positive trial results for the study called DECIDE were already released earlier in June this year. However, detailed data will be presented in the conference. Daclizumab high yield process (DAC HYP), a novel therapy, has been developed for the treatment of Relapsing Remitting Multiple Sclerosis (RRMS).

Receptos Inc (RCPT) will also present from phase II RADIANCE trial data for its RRMS drug, RPC1063, in the conference. Synthetic Biologics Inc (SYN) will report detailed results for its Phase II trials of Trimesta, an oral estriol drug. The trial investigates cognitive and disability improvement in female RRMS patients when used in combination with Teva’s RMSS drug, Copaxone.

FDA Approval of Actavis

Tomorrow, the US Food and Drug Administration (FDA)’s Drugs Advisory Committee panel will review the New Drug Application (NDA) submitted by Actavis plc’s (ACT) in February. The NDA relates to a fixed-dose combination of Nebivolol and Valsartan for the treatment of hyper tension, being developed by the company’s holding Forest laboratories. On September 5, FDA issued a briefing for tomorrow’s meeting, which raised questions on whether the improvements from the drug were clinically significant.

FDA’s Decision On Takeda’s Drug

Another important development will be the FDA’s pending decision about Takeda Pharmaceutical Co Ltd (ADR) (TKPYY) and Orexigen Therapeutics, Inc.’s (OREX) NDA for Contrave. The PDUFA (Prescription Drug User Fee Act) date for Contrave, deadline for the regulatory authority to approve a drug, is set for Thursday, September 11. Contrave is an obesity drug, designed to manage weight loss in obese individuals.


This link:http://www.chemcd.com/news/3919.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.